PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs
about
sameAs
Enzymes of the cyclooxygenase pathways of prostanoid biosynthesisAllellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma.Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer riskA meta-analysis of PTGS1 and PTGS2 polymorphisms and NSAID intake on the risk of developing cancerPolymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort studyCyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trialPolymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control studyGenetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma.-765G > C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia.Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family RegistryRole of COX-2 activity and CRP levels in patients with non-melanoma skin cancer. -765G>C PTGS2 polymorphism and NMSC risk.Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer riskInteraction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer riskCOX-2-765G>C polymorphism increases the risk of cancer: a meta-analysis.PharmGKB summary: very important pharmacogene information for PTGS2.The risk of coronary thrombosis with cyclo-oxygenase-2 inhibitors does not vary with polymorphisms in two regions of the cyclo-oxygenase-2 genePolymorphic human prostaglandin H synthase-2 proteins and their interactions with cyclooxygenase substrates and inhibitors.Cyclooxygenase-2 gene polymorphisms and the risk of colorectal cancer: A population-based study.Bioactive food components, inflammatory targets, and cancer prevention.Genetic polymorphisms in the cyclooxygenase-1 and cyclooxygenase-2 genes and risk of colorectal adenoma.The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway.Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics.IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry.PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, and FLAP SNPs: interaction with fatty acids in colon cancer and rectal cancer.Linkage disequilibrium and haplotype analysis of COX-2 and risk of colorectal adenoma development.Biphasic responses of human vascular smooth muscle cells to magnesium ion.C-reactive protein genotypes and haplotypes, polymorphisms in NSAID-metabolizing enzymes, and risk of colorectal polypsGenetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.A review of gene-drug interactions for nonsteroidal anti-inflammatory drug use in preventing colorectal neoplasia.Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesionsNo association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk.A study of prostaglandin pathway genes and interactions with current nonsteroidal anti-inflammatory drug use in colorectal adenoma.Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: a study from northern IndiaCOX-2 polymorphisms -765G-->C and -1195A-->G and colorectal cancer riskCOX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.Sp1 and the 'hallmarks of cancer'.SP and KLF Transcription Factors in Digestive Physiology and Diseases.Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial.Polymorphisms in arachidonic acid metabolism-related genes and the risk and prognosis of colorectal cancer.Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case-control study.
P2860
Q24630614-C59514D5-FEAE-4557-8562-A6D002BD291DQ25255846-4818A12F-68E8-4ECC-8C8C-3A5018ADD68FQ28213217-93C50703-308C-406B-8218-FD9204F17CC8Q28535310-A48C13ED-3A0E-4990-A20E-18F85011DAD6Q30907350-7D8717F1-46DB-426C-A173-3C2D608D1F75Q33503521-B72C8743-A559-480E-8B30-D8A3DA4EF20BQ33741123-256850A1-2430-4A11-8401-C208D60FC675Q33770260-4B05E46F-CF84-434B-ADE8-CA22927A1349Q33869492-0AE4CC9A-B751-4EE8-A553-0BED2EFCE40FQ34096843-C02E6F16-B03F-4387-A1EC-E20B7E62569AQ34096844-E9960F4E-EA30-46B4-8F1B-17E3F249201FQ34179634-418AD093-D43F-42E9-8CCA-E849F115A548Q34794017-86A713DC-63DA-4E70-86FB-5D1C2CCFC20AQ34984281-71F3928A-9B46-44D1-AFF6-AB8081B40E48Q35120350-797FE30A-6F69-47A0-AAB3-9EF61DA38999Q35373720-EE5DB7C2-7052-436F-8648-03BE176DDAECQ35737180-2349B805-47E7-4B43-A828-69B4E69770ADQ35944431-2028FA18-BABD-4A15-B27B-56606AC37DE1Q36254183-39E4073A-BF08-442D-A997-A81EBFC08DB1Q36290438-F9386836-BD03-4CBC-8902-9A42BA0E955DQ36339264-6B10D4FA-6730-4BAF-ADE4-3C5964CAE29FQ36402212-DE581CD7-4EB8-4A62-A447-D6097B8A502EQ36499740-CB8FADA4-C6E5-4779-A747-F82EB18310FDQ36501999-78493D78-3BAF-4204-8D2D-C118535580E6Q36746417-75A2E067-E061-4CCE-95E2-D8161BBDABFBQ36919703-80345E5F-E195-4A01-B26B-F84A199C88A7Q36950564-6DAF6A61-38B2-4A7E-901F-16E4DC094F76Q36974684-579F4200-56CB-4C8C-B75E-7C17BDBE8C43Q37016763-8D10B94B-94FB-42E1-9037-6573079F749CQ37152159-E488AFC7-C252-4A6A-9B2C-45F617892B05Q37192639-30D974A2-AF37-4F60-A0AB-63E52B3E23B9Q37213095-71C01C48-85E6-44F8-8550-7685F08BBB03Q37220827-81ADE8C9-5C99-4C09-B0BD-EAD6DC91B1DCQ37362878-C8C861B7-491F-4F63-8A11-C07265DCBD0DQ37554165-E39F6959-609E-4FB8-B42F-2FEA29CD97B5Q38267908-538FB5A7-43FF-4663-A887-CAD4254FEC31Q39214035-44FEFD08-B8E7-4E9A-90EF-CBFB1FE208B0Q41404998-973173A9-9826-4100-9BE9-4FBAF5CDD78DQ44452085-42A86A77-64F8-4DBB-BCA5-C39F8FC42763Q44934975-0E791A2C-C1B3-4F17-9474-1F464338FD3C
P2860
PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs
description
2005 nî lūn-bûn
@nan
2005 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մարտին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
PTGS2 (COX-2) -765G > C promot ...... roidal anti-inflammatory drugs
@ast
PTGS2 (COX-2) -765G > C promot ...... roidal anti-inflammatory drugs
@en
PTGS2 (COX-2) -765G > C promot ...... roidal anti-inflammatory drugs
@nl
type
label
PTGS2 (COX-2) -765G > C promot ...... roidal anti-inflammatory drugs
@ast
PTGS2 (COX-2) -765G > C promot ...... roidal anti-inflammatory drugs
@en
PTGS2 (COX-2) -765G > C promot ...... roidal anti-inflammatory drugs
@nl
prefLabel
PTGS2 (COX-2) -765G > C promot ...... roidal anti-inflammatory drugs
@ast
PTGS2 (COX-2) -765G > C promot ...... roidal anti-inflammatory drugs
@en
PTGS2 (COX-2) -765G > C promot ...... roidal anti-inflammatory drugs
@nl
P2093
P1476
PTGS2 (COX-2) -765G > C promot ...... roidal anti-inflammatory drugs
@en
P2093
Cornelia M Ulrich
Jeannette Bigler
John Whitton
Joon-Ho Yu
Justin Sibert
Rachel Sparks
P356
10.1158/1055-9965.EPI-04-0510
P407
P50
P577
2005-03-01T00:00:00Z